New technique to diagnose cancer metastasis uses origami nanoprobes

Th, 22.8.2024 | Original article from: JHU HUB / Jonathan Deutschman
A team of Johns Hopkins engineers can locate aggressive cancers using laser light and folded DNA
  • Photo: Johns Hopkins University / Getty Images: New technique to diagnose cancer metastasis uses origami nanoprobes
  • Video: MDScienceCenter: 2016 Outstanding Young Engineer Recipient: Ishan Barman, Ph.D.

Johns Hopkins engineers have created a new optical tool that could improve cancer imaging. Their approach, called SPECTRA, uses tiny nanoprobes that light up when they attach to aggressive cancer cells, helping clinicians distinguish between localized cancers and those that are metastatic and have the potential to spread throughout the body.

"Our findings show that SPECTRA has huge potential for cancer detection and imaging," said team leader Ishan Barman, a professor of mechanical engineering at the Whiting School of Engineering. "We're giving clinicians a more powerful tool that can find cancer cells earlier and more precisely than ever before."

The team's research appears in Advanced Functional Materials.

Johns Hopkins University / Getty Images: New technique to diagnose cancer metastasis uses origami nanoprobes.Johns Hopkins University / Getty Images: New technique to diagnose cancer metastasis uses origami nanoprobes.

Scalable and more cost-effective than current methods, SPECTRA leverages a first-of-its-kind combination: Raman spectroscopy—which uses the scattering of laser light to provide detailed information about molecular vibrations—and DNA origami, which involves folding DNA into specific shapes, as in the Japanese art of paper-folding. The team used the folded DNA as a scaffold to create precisely arranged plasmonic nanoparticles, Raman reporters (a molecule that produces a strong signal when analyzed using Raman spectroscopy), and cancer-targeting DNA sequences. These multifunctional nanoprobes were then tested on cancer cells.

The team found that, unlike CT or MRI scans that can indicate the presence of a tumor but not the specific molecular signatures that can alert physicians to current or impending metastasis, SPECTRA effectively and consistently bound to metastatic prostate cancer DU145 cells and even differentiated between those and non-metastatic cells.

In addition, the researchers selected a Raman reporter—a signaling molecule—that results in an active and distinct signal in a range that made it stand out clearly against the background of normal tissue, helping clinicians more precisely locate disease.

"It's a smart design that gives high enhancement to the Raman signal, and it's uniform," said team member Swati Tanwar, a postdoctoral fellow in mechanical engineering. "It can distinguish aggressive cancer cells from non-aggressive based on the intensity of the signal. In a tumor, if 10% of the cells are aggressive and 90% are non-aggressive, the 10% will light up and give a very high signal."

Tanwar said that each strand of DNA in the origami scaffold has a unique sequence and occupies a specific position in the folded origami nanostructure. This meticulous arrangement facilitated the creation of multifunctional SPECTRA nanoprobe.

"Raman spectroscopy is a molecular fingerprinting tool," said team member Lintong Wu, a PhD student in mechanical engineering. "Molecules can look similar at a distance, but using Raman spectroscopy they show different peaks and signals throughout the entire spectrum."

Johns Hopkins University
LinkedIn Logo
 

Related articles

Conference CEEPC/IPM/CMSC 2022 (Day 2)
Article | Events

Conference CEEPC/IPM/CMSC 2022 (Day 2)

The second day of the joint conference on mass spectrometry and proteomics in 2022 brought 17 lectures, a poster section and the presentation of the Zdenek Herman award.
Preventing early-onset colorectal cancers aim of $25 million award
Article | Health

Preventing early-onset colorectal cancers aim of $25 million award

Washington University, School of Medicine in St. Louis leads international team funded by Cancer Grand Challenges.
Kristýna Boušová: Engineering new proteins
Article | Scientists

Kristýna Boušová: Engineering new proteins

From an early age, she was fascinated by the microworld of cells and molecules. But she didn’t just want to observe it – she began to actively transform it.
Unraveling Neuroendocrine Cancer Research with Mass Spectrometry
Interview | Science and research

Unraveling Neuroendocrine Cancer Research with Mass Spectrometry

Dr. Rachael Guenter traces her path into neuroendocrine tumor research and explains how clinician partnerships and mass spectrometry accelerate translational discoveries—plus why “think zebras” matters.
 

Related articles

Conference CEEPC/IPM/CMSC 2022 (Day 2)
Article | Events

Conference CEEPC/IPM/CMSC 2022 (Day 2)

The second day of the joint conference on mass spectrometry and proteomics in 2022 brought 17 lectures, a poster section and the presentation of the Zdenek Herman award.
Preventing early-onset colorectal cancers aim of $25 million award
Article | Health

Preventing early-onset colorectal cancers aim of $25 million award

Washington University, School of Medicine in St. Louis leads international team funded by Cancer Grand Challenges.
Kristýna Boušová: Engineering new proteins
Article | Scientists

Kristýna Boušová: Engineering new proteins

From an early age, she was fascinated by the microworld of cells and molecules. But she didn’t just want to observe it – she began to actively transform it.
Unraveling Neuroendocrine Cancer Research with Mass Spectrometry
Interview | Science and research

Unraveling Neuroendocrine Cancer Research with Mass Spectrometry

Dr. Rachael Guenter traces her path into neuroendocrine tumor research and explains how clinician partnerships and mass spectrometry accelerate translational discoveries—plus why “think zebras” matters.
 

Related articles

Conference CEEPC/IPM/CMSC 2022 (Day 2)
Article | Events

Conference CEEPC/IPM/CMSC 2022 (Day 2)

The second day of the joint conference on mass spectrometry and proteomics in 2022 brought 17 lectures, a poster section and the presentation of the Zdenek Herman award.
Preventing early-onset colorectal cancers aim of $25 million award
Article | Health

Preventing early-onset colorectal cancers aim of $25 million award

Washington University, School of Medicine in St. Louis leads international team funded by Cancer Grand Challenges.
Kristýna Boušová: Engineering new proteins
Article | Scientists

Kristýna Boušová: Engineering new proteins

From an early age, she was fascinated by the microworld of cells and molecules. But she didn’t just want to observe it – she began to actively transform it.
Unraveling Neuroendocrine Cancer Research with Mass Spectrometry
Interview | Science and research

Unraveling Neuroendocrine Cancer Research with Mass Spectrometry

Dr. Rachael Guenter traces her path into neuroendocrine tumor research and explains how clinician partnerships and mass spectrometry accelerate translational discoveries—plus why “think zebras” matters.
 

Related articles

Conference CEEPC/IPM/CMSC 2022 (Day 2)
Article | Events

Conference CEEPC/IPM/CMSC 2022 (Day 2)

The second day of the joint conference on mass spectrometry and proteomics in 2022 brought 17 lectures, a poster section and the presentation of the Zdenek Herman award.
Preventing early-onset colorectal cancers aim of $25 million award
Article | Health

Preventing early-onset colorectal cancers aim of $25 million award

Washington University, School of Medicine in St. Louis leads international team funded by Cancer Grand Challenges.
Kristýna Boušová: Engineering new proteins
Article | Scientists

Kristýna Boušová: Engineering new proteins

From an early age, she was fascinated by the microworld of cells and molecules. But she didn’t just want to observe it – she began to actively transform it.
Unraveling Neuroendocrine Cancer Research with Mass Spectrometry
Interview | Science and research

Unraveling Neuroendocrine Cancer Research with Mass Spectrometry

Dr. Rachael Guenter traces her path into neuroendocrine tumor research and explains how clinician partnerships and mass spectrometry accelerate translational discoveries—plus why “think zebras” matters.